StockMacro
Menu

Enovis

$25.47 +4.9% in 6 monthsMarket cap $1.5B

ENOV on XNYS, Health Care, Enovis Corporation, job postings

Measures activity, not value. Not investment advice.

Shares rose 22% in a month while short interest reached 18%, 1.6 times its level a year earlier.

  • BadNet loss $527.4M over 12 months on $2.3B revenue
  • WatchCapital spending down 32% to $36.5M in the latest quarter

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 2 Oct 2026

Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.

Industry
Orthopedic, prosthetic & surgical appliances & supplies (Health Care)
Employees
7,802
Website
enovis.com
Listed
NYSE, US
Last results
5 Nov 2026
Next results
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 2 Oct 2026: revenue $558.7M, net income $3.1M.
Quarter to 31 Dec 2021: revenue $399.1M, net income -$1.9MQuarter to 31 Dec 2021: revenue $399.1M, net income -$1.9MQuarter to 1 Apr 2022: revenue $1.0B, net income $16.3MQuarter to 1 Apr 2022: revenue $1.0B, net income $16.3MQuarter to 1 Jul 2022: revenue $395.1M, net income $76.9MQuarter to 1 Jul 2022: revenue $395.1M, net income $76.9MQuarter to 30 Sep 2022: revenue $383.8M, net income -$66.6MQuarter to 30 Sep 2022: revenue $383.8M, net income -$66.6MQuarter to 31 Dec 2022: revenue $408.7M, net income -$38.6MQuarter to 31 Dec 2022: revenue $408.7M, net income -$38.6MQuarter to 31 Mar 2023: revenue $406.2M, net income -$23.4MQuarter to 31 Mar 2023: revenue $406.2M, net income -$23.4MQuarter to 30 Jun 2023: revenue $428.5M, net income -$10.0MQuarter to 30 Jun 2023: revenue $428.5M, net income -$10.0MQuarter to 29 Sep 2023: revenue $417.5M, net income -$2.9MQuarter to 29 Sep 2023: revenue $417.5M, net income -$2.9MQuarter to 31 Dec 2023: revenue –, net income $3.0MQuarter to 29 Mar 2024: revenue $516.3M, net income -$72.0MQuarter to 29 Mar 2024: revenue $516.3M, net income -$72.0MQuarter to 28 Jun 2024: revenue $525.2M, net income -$18.6MQuarter to 28 Jun 2024: revenue $525.2M, net income -$18.6MQuarter to 27 Sep 2024: revenue $505.2M, net income -$31.5MQuarter to 27 Sep 2024: revenue $505.2M, net income -$31.5MQuarter to 31 Dec 2024: revenue $561.0M, net income -$703.3MQuarter to 31 Dec 2024: revenue $561.0M, net income -$703.3MQuarter to 4 Apr 2025: revenue $558.8M, net income -$56.0MQuarter to 4 Apr 2025: revenue $558.8M, net income -$56.0MQuarter to 4 Jul 2025: revenue $564.5M, net income -$36.7MQuarter to 4 Jul 2025: revenue $564.5M, net income -$36.7MQuarter to 3 Oct 2025: revenue $548.9M, net income -$571.1MQuarter to 3 Oct 2025: revenue $548.9M, net income -$571.1MQuarter to 31 Dec 2025: revenue $575.8M, net income -$520.6MQuarter to 31 Dec 2025: revenue $575.8M, net income -$520.6MQuarter to 3 Apr 2026: revenue $589.2M, net income -$8.8MQuarter to 3 Apr 2026: revenue $589.2M, net income -$8.8MQuarter to 3 Jul 2026: revenue $582.8M, net income -$1.2MQuarter to 3 Jul 2026: revenue $582.8M, net income -$1.2MQuarter to 2 Oct 2026: revenue $558.7M, net income $3.1MQuarter to 2 Oct 2026: revenue $558.7M, net income $3.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $1.0B2 Oct 2026
See the numbers
Quarter toRevenueNet income
2 Oct 2026$558.7M$3.1M
3 Jul 2026$582.8M-$1.2M
3 Apr 2026$589.2M-$8.8M
31 Dec 2025$575.8M-$520.6M
3 Oct 2025$548.9M-$571.1M
4 Jul 2025$564.5M-$36.7M
4 Apr 2025$558.8M-$56.0M
31 Dec 2024$561.0M-$703.3M
27 Sep 2024$505.2M-$31.5M
28 Jun 2024$525.2M-$18.6M
29 Mar 2024$516.3M-$72.0M
31 Dec 2023–$3.0M
29 Sep 2023$417.5M-$2.9M
30 Jun 2023$428.5M-$10.0M
31 Mar 2023$406.2M-$23.4M
31 Dec 2022$408.7M-$38.6M
30 Sep 2022$383.8M-$66.6M
1 Jul 2022$395.1M$76.9M
1 Apr 2022$1.0B$16.3M
31 Dec 2021$399.1M-$1.9M
Fundamentals, 12 months to 2 Oct 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $2.3B $2.2B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +3.3% +8.1%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$527.4M -$1.4B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$9.22 -$24.31
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 61.3% 58.4% 61.3%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -20.6% -57.6% 5.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -22.9% -61.2% -2.7%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -30.0% -20.0%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $69.6M $22.8M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $13.0M $33.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $1.3B $1.4B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $1.2B $1.3B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.84 0.22
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $25.88
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 27.5
P/SPrice to sales: market cap divided by revenue of the last 12 months. 0.64 2.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 1.2 3.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.98 3.4

Latest = 12 months to 2 Oct 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
EnovisENOV (this company) $1.5Bloss0.64+3.3%-22.9%
CadreCDRE $1.3B30.81.7+18%5.6%
Establishment LabsESTA $2.1Bloss7.8+38%-14.6%
Anteris Technologies GlobalAVR $486.5Mloss209+9.0%–
Mine SafetyMSA $6.5B21.63.3+8.1%15.0%
Sanara MedTechSMTI $298.9Mloss2.7+9.8%-2.7%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$649K

bought $649K, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-3.2%

241 13F filers vs 249

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

70.4M shares held by 13F filers (30 Sep 2026) of 57.7M outstanding (30 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

18%

10.6M shares sold short (30 Oct 2026) of 57.7M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.3

10.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-9.8%

11.7M shares sold short in the report before, 10.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

52%

52% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 57%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+1.8%

$558.7M vs $548.9M (quarter ended 2 Oct 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-32%

$36.5M vs $53.5M (quarter ended 2 Oct 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$250K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

14

14 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

14×

14 articles in the last 7 days; its usual week has 1.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 11.7M, 1.6× a year earlier

Price $25.47 on 20 Nov 2026, -5.1% over 12 months (12-month range $17.43 to $31.42)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $842K in the last 12 months (the 12 months before: $739K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 5 published in the last 12 months, +400% on the 12 months before.
Revenue per quarter. Revenue $558.7M in the latest quarter, +1.8% on a year earlier.
Capital spending per quarter. Capital spending $36.5M in the latest quarter, -32% on a year earlier.
Institutional holders (13F filers). 241 13F filers reported holding it in the latest 13F quarter, -10% on a year earlier.
Lobbying spend. Lobbying spend: $250K published in the last 12 months, +56% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
27 Oct 2026Sharp changeShort interest spike: short interest spike, 11.7M vs usual 8.5M (2026-10-15); 1.6x the same period a year earlier
19 May 20268-K and other filingsDirector or officer change
19 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Dec 20258-K and other filingsDirector or officer change
14 Nov 20258-K and other filingsDirector or officer change
14 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Oct 2025Sharp changeLobbying on a new issue: lobbying on a new issue: BUD, TRD (2025-09-30)
1 Oct 2025Lobbying filingnew lobbying registration (CONSTITUTION PARTNERS)
26 Aug 2025Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 464K)
2 Apr 20258-K and other filingsDirector or officer change
14 Mar 20258-K and other filingsDirector or officer change
26 Feb 20258-K and other filingsDirector or officer change
26 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 May 20248-K and other filingsDirector or officer change
22 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Apr 2024Lobbying filingnew lobbying registration (HEALTH POLICY SOURCE, INC.)
16 Apr 2024Lobbying filinglobbying engagement terminated (BROWNSTEIN HYATT FARBER SCHRECK, LLP)
20 Feb 2024Sharp changeMany funds opening a new position: many funds opening a new position, 51 vs usual 35.50 (2023-12-31); 1.8x the same period a year earlier
3 Jan 20248-K and other filingsCompleted an acquisition or asset sale
5 Dec 20238-K and other filingsDirector or officer change
5 Dec 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 May 20238-K and other filingsDirector or officer change
15 Mar 20238-K and other filingsDirector or officer change
3 Jan 20238-K and other filingsDirector or officer change
3 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Oct 2022Lobbying filinglobbying engagement terminated (W STRATEGIES, LLC)
30 Sep 2022Lobbying filingnew lobbying registration (BROWNSTEIN HYATT FARBER SCHRECK, LLP)
9 Aug 2022Sharp changeQuarterly revenue change: quarterly revenue change, 395.1M vs usual 853.7M (2022-07-01); 0.4x the same period a year earlier
20 Jul 2022Lobbying filinglobbying engagement terminated (HEALTH POLICY SOURCE, INC.)
30 Jun 20228-K and other filingsDirector or officer change
13 Jun 20228-K and other filingsDirector or officer change
8 Apr 20228-K and other filingsCompleted an acquisition or asset sale
8 Apr 20228-K and other filingsDirector or officer change
11 Mar 20228-K and other filingsDirector or officer change
25 Feb 20228-K and other filingsDirector or officer change
8 Feb 20228-K and other filingsDirector or officer change
8 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$297K published
Month from 1 Feb 2022: -$668K published
Month from 1 Mar 2022: -$9.5M published
Month from 1 Jul 2022: -$2K published
Month from 1 Aug 2022: -$196K published
Month from 1 Nov 2022: -$3.7M published
Month from 1 Dec 2022: -$76K published
Month from 1 Feb 2023: -$909K published
Month from 1 Mar 2023: -$3.0M published
Month from 1 Apr 2023: -$37K published
Month from 1 May 2023: -$80K published
Month from 1 Jun 2023: -$35K published
Month from 1 Jul 2023: -$4K published
Month from 1 Aug 2023: -$10K published
Month from 1 Aug 2025: $464K published
Month from 1 Sep 2025: $200K published
Month from 1 Nov 2025: $75K published
Month from 1 Dec 2025: -$45K published
Month from 1 Mar 2026: $146K published
Month from 1 Jun 2026: $92K published
Month from 1 Sep 2026: $450K published
Month from 1 Nov 2026: $199K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Apr 2025: 1 published
Quarter from 1 Jul 2026: 1 published
Quarter from 1 Oct 2026: 4 published
Revenue per quarter
Quarter ended 31 Dec 2021: $399.1M, -52% on a year earlier; public on 2 Mar 2023
Quarter ended 1 Apr 2022: $1.0B, +16% on a year earlier; public on 11 May 2022
Quarter ended 1 Jul 2022: $395.1M, -60% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $383.8M, -60% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $408.7M, +2.4% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $406.2M, -60% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $428.5M, +8.4% on a year earlier; public on 4 Aug 2023
Quarter ended 29 Sep 2023: $417.5M, +8.8% on a year earlier; public on 8 Nov 2023
Quarter ended 29 Mar 2024: $516.3M, +27% on a year earlier; public on 3 May 2024
Quarter ended 28 Jun 2024: $525.2M, +23% on a year earlier; public on 8 Aug 2024
Quarter ended 27 Sep 2024: $505.2M, +21% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $561.0M; public on 27 Feb 2025
Quarter ended 4 Apr 2025: $558.8M, +8.2% on a year earlier; public on 9 May 2025
Quarter ended 4 Jul 2025: $564.5M, +7.5% on a year earlier; public on 8 Aug 2025
Quarter ended 3 Oct 2025: $548.9M, +8.6% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $575.8M, +2.6% on a year earlier; public on 27 Feb 2026
Quarter ended 3 Apr 2026: $589.2M, +5.4% on a year earlier; public on 8 May 2026
Quarter ended 3 Jul 2026: $582.8M, +3.2% on a year earlier; public on 7 Aug 2026
Quarter ended 2 Oct 2026: $558.7M, +1.8% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $30.6M, -7.7% on a year earlier; public on 23 Feb 2022
Quarter ended 1 Apr 2022: $24.1M, -1.8% on a year earlier; public on 11 May 2022
Quarter ended 1 Jul 2022: $23.7M, +18% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $20.9M, -28% on a year earlier; public on 3 Nov 2022
Quarter ended 31 Dec 2022: $36.8M, +20% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $30.4M, +26% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $36.8M, +55% on a year earlier; public on 4 Aug 2023
Quarter ended 29 Sep 2023: $27.0M, +30% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $27.9M, -24% on a year earlier; public on 23 Feb 2024
Quarter ended 29 Mar 2024: $36.9M, +21% on a year earlier; public on 3 May 2024
Quarter ended 28 Jun 2024: $39.4M, +7.1% on a year earlier; public on 8 Aug 2024
Quarter ended 27 Sep 2024: $51.2M, +89% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $53.2M, +90% on a year earlier; public on 27 Feb 2025
Quarter ended 4 Apr 2025: $43.3M, +17% on a year earlier; public on 9 May 2025
Quarter ended 4 Jul 2025: $44.4M, +13% on a year earlier; public on 8 Aug 2025
Quarter ended 3 Oct 2025: $53.5M, +4.5% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $56.3M, +5.8% on a year earlier; public on 27 Feb 2026
Quarter ended 3 Apr 2026: $52.8M, +22% on a year earlier; public on 8 May 2026
Quarter ended 3 Jul 2026: $43.9M, -1.1% on a year earlier; public on 7 Aug 2026
Quarter ended 2 Oct 2026: $36.5M, -32% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 290; public on 14 Feb 2022
31 Mar 2022 report: 283; public on 16 May 2022
30 Jun 2022 report: 234; public on 15 Aug 2022
30 Sep 2022 report: 228; public on 14 Nov 2022
31 Dec 2022 report: 232; public on 14 Feb 2023
31 Mar 2023 report: 238; public on 15 May 2023
30 Jun 2023 report: 243; public on 14 Aug 2023
30 Sep 2023 report: 249; public on 14 Nov 2023
31 Dec 2023 report: 275; public on 14 Feb 2024
31 Mar 2024 report: 276; public on 15 May 2024
30 Jun 2024 report: 270; public on 14 Aug 2024
30 Sep 2024 report: 272; public on 14 Nov 2024
31 Dec 2024 report: 277; public on 14 Feb 2025
31 Mar 2025 report: 280; public on 15 May 2025
30 Jun 2025 report: 273; public on 14 Aug 2025
30 Sep 2025 report: 268; public on 14 Nov 2025
31 Dec 2025 report: 245; public on 17 Feb 2026
31 Mar 2026 report: 249; public on 15 May 2026
30 Jun 2026 report: 249; public on 14 Aug 2026
30 Sep 2026 report: 241; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $20K published
Quarter from 1 Apr 2022: $20K published
Quarter from 1 Jul 2022: $20K published
Quarter from 1 Oct 2022: $60K published
Quarter from 1 Jan 2023: $50K published
Quarter from 1 Apr 2023: $50K published
Quarter from 1 Jul 2023: $50K published
Quarter from 1 Oct 2023: $50K published
Quarter from 1 Jan 2024: $50K published
Quarter from 1 Apr 2024: $50K published
Quarter from 1 Jul 2024: $20K published
Quarter from 1 Oct 2024: $20K published
Quarter from 1 Jan 2025: $40K published
Quarter from 1 Apr 2025: $40K published
Quarter from 1 Jul 2025: $50K published
Quarter from 1 Oct 2025: $30K published
Quarter from 1 Jan 2026: $65K published
Quarter from 1 Apr 2026: $65K published
Quarter from 1 Jul 2026: $65K published
Quarter from 1 Oct 2026: $55K published

What is unusual now

  • Made public in the last 90 days: it had 11.7M shares sold short in the 15 Oct 2026 report, 1.6× the same report last year.
  • Short interest spike: had 11.7M shares sold short in the 15 Oct 2026 report, 1.6× the same report last year Public on 27 Oct 2026.
  • Insider net buying (open market): Insiders bought a net $842K in the last 12 months (the 12 months before: $739K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 5 published in the last 12 months, +400% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: no sales; 7 purchases, $649K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
16 Nov 2026Angela S LalorDirectorBuy1,754$28.16$49KForm 4
12 Nov 2026Sharon L WienbarDirectorBuy1,774$28.09$50KForm 4
12 Nov 2026Angela S LalorDirectorBuy1,757$28.57$50KForm 4
10 Nov 2026Sharon L WienbarDirectorBuy1,831$27.26$50KForm 4
8 Sep 2026Oliver EngertChief Administrative OfficerBuy2,660$18.80$50KForm 4
4 Sep 2026Oliver EngertChief Administrative OfficerBuy7,598$19.74$150KForm 4
4 Sep 2026Damien McDonaldChief Executive OfficerBuy13,035$19.15$250KForm 4
16 Jun 2026Oliver EngertChief Administrative OfficerBuy1,000$20.92$21KForm 4

241 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 35 opened a position, 44 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.10.3M17.9%$188.4M+18K+0.2%
American Century Companies Inc6.9M11.9%$125.9M+783K+13%
Rubric Capital Management LP5.3M9.19%$96.8M+1.4M+36%
Vanguard Portfolio Management LLC3.7M6.45%$67.9M-208K-5.3%
State Street Corp2.5M4.34%$45.7M+39K+1.6%
Vanguard Capital Management LLC2.4M4.25%$44.8M-35K-1.4%
Hood River Capital Management LLC2.3M4.06%$42.8M+43K+1.9%
Dimensional Fund Advisors LP2.3M4.05%$42.7M+593K+34%
Morgan Stanley1.9M3.21%$33.8M+783K+73%
Private Management Group Inc1.8M3.11%$32.7M+427K+31%

Company events

All 48 company events

In 12 months: 2 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
19 May 2026Director or officer changeSame filing: shareholder vote results8-K
15 Dec 2025Director or officer change8-K
10 Dec 2025Signed a major agreementSame filing: took on new debt8-K
14 Nov 2025Director or officer change8-K
2 Apr 2025Director or officer change8-K
14 Mar 2025Director or officer change8-K
26 Feb 2025Director or officer change8-K
22 May 2024Director or officer changeSame filing: changed its bylaws or fiscal year, shareholder vote results8-K

Reported lobbying spend: $55K in Q3 2026, $65K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Sep 2025NewConstitution Partnersfor EnovisIssues related to military medical suppliesDefenseFiling
15 Apr 2024NewHealth Policy Source, Inc.for EnovisMedicare DME Competitive Bidding reforms and refinements, prior authorization reforms - legislative and regulatory, and Implementation of the No Pain ActMedicare/MedicaidFiling
1 Mar 2024EndedBrownstein Hyatt Farber Schreck, LLPfor Enovis CorporationDurable medical equipment coverage and reimbursement Prior authorizationHealth issuesFiling
31 Jul 2022EndedW Strategies, LLCfor EnovisGeneral Medicare issues affecting durable medical equipment (DME) reimbursement and regulation, including CMS competitive bidding and prior authorization requirements.Medicare/MedicaidFiling
1 Jul 2022NewBrownstein Hyatt Farber Schreck, LLPfor Enovis CorporationDurable medical equipment coverage and reimbursement Prior authorizationHealth issuesFiling
1 Apr 2022EndedHealth Policy Source, Inc.for Colfax CorporationMedicare CME CB MatterMedicare/MedicaidFiling
15 Feb 2021NewHealth Policy Source, Inc.for Colfax CorporationMedicare CME CB MatterMedicare/MedicaidFiling
21 Dec 2010EndedBrown And Company, Inc.for Colfax CorporationDefense Authorization and Appropriation Bills and Defense ProgramsDefenseFiling

The 5 newest of 116 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 17 Nov 2026Insiders record

    Lalor Angela S (director) bought 1,754 shares of ENOV ($49,386) (dated 16 Nov 2026)

  2. 13 Nov 2026Insiders record

    Wienbar Sharon L (director) bought 1,774 shares of ENOV ($49,832) (dated 12 Nov 2026)

  3. 13 Nov 2026Insiders record

    Lalor Angela S (director) bought 1,757 shares of ENOV ($50,193) (dated 12 Nov 2026)

  4. 11 Nov 2026Insiders record

    Wienbar Sharon L (director) bought 1,831 shares of ENOV ($49,917) (dated 10 Nov 2026)

  5. 27 Oct 2026Short interest and volume change

    had 11.7M shares sold short in the 15 Oct 2026 report, 1.6× the same report last year.

    Same report last year: 7.2M; its normal report is 8.5M.

    See the evidence
    This period
    11.7M (the 15 Oct 2026 report)
    Normal report (median of 24 earlier)
    8.5M
    Typical spread (median absolute deviation)
    396K
    How far from its usual level
    +3.8
    Same report last year
    7.2M
    History used
    1,645 days
    2025-10-15: 7.2M2025-10-31: 7.7M2025-11-14: 7.8M2025-11-28: 8.4M2025-12-15: 8.4M2025-12-31: 7.9M2026-01-15: 8.1M2026-01-30: 8.7M2026-02-13: 8.7M2026-02-27: 8.0M2026-03-13: 8.0M2026-03-31: 8.1M2026-04-15: 8.6M2026-04-30: 9.2M2026-05-15: 8.4M2026-05-29: 8.7M2026-06-15: 9.0M2026-06-30: 9.5M2026-07-15: 8.3M2026-07-31: 8.5M2026-08-14: 8.7M2026-08-31: 9.1M2026-09-15: 9.5M2026-09-30: 10.6M2026-10-15: 11.7M
    the 15 Oct 2026 report24 earlier reportsnormal: 8.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 9 Sep 2026Insiders record

    Engert Oliver (Chief Administrative Officer) bought 2,660 shares of ENOV ($50,008) (dated 8 Sep 2026)

  7. 5 Sep 2026Insiders record

    Engert Oliver (Chief Administrative Officer) bought 7,598 shares of ENOV ($149,971) (dated 4 Sep 2026)

  8. 5 Sep 2026Insiders record

    McDonald Damien (Chief Executive Officer) bought 13,035 shares of ENOV ($249,620) (dated 4 Sep 2026)

  9. 17 Jun 2026Insiders record

    Engert Oliver (Chief Administrative Officer) bought 1,000 shares of ENOV ($20,920) (dated 16 Jun 2026)

  10. 16 Jun 2026Insiders record

    Engert Oliver (Chief Administrative Officer) bought 1,200 shares of ENOV ($25,948) (dated 15 Jun 2026)

  11. 12 Jun 2026Insiders record

    Engert Oliver (Chief Administrative Officer) bought 1,000 shares of ENOV ($23,000) (dated 11 Jun 2026)

  12. 4 Jun 2026Insiders record

    Engert Oliver (Chief Administrative Officer) bought 1,000 shares of ENOV ($22,220) (dated 3 Jun 2026)

  13. 19 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 19 May 2026Filings record

    Director or officer change

  15. 17 Mar 2026Insiders record

    Engert Oliver (Chief Administrative Officer) bought 1,000 shares of ENOV ($23,740) (dated 16 Mar 2026)

  16. 13 Mar 2026Insiders record

    Engert Oliver (Chief Administrative Officer) bought 1,000 shares of ENOV ($23,930) (dated 12 Mar 2026)

  17. 11 Mar 2026Insiders record

    Engert Oliver (Chief Administrative Officer) bought 1,750 shares of ENOV ($41,700) (dated 10 Mar 2026)

  18. 6 Mar 2026Insiders record

    Engert Oliver (Chief Administrative Officer) bought 1,250 shares of ENOV ($31,045) (dated 5 Mar 2026)

  19. 4 Mar 2026Insiders record

    Engert Oliver (Chief Administrative Officer) bought 1,000 shares of ENOV ($25,500) (dated 3 Mar 2026)

  20. 15 Dec 2025Filings record

    Director or officer change

  21. 29 Nov 2025Insiders record

    KLECKNER JOHN (Principal Accounting Officer) bought 2,468 shares of ENOV ($74,830) (dated 28 Nov 2025)

  22. 14 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 14 Nov 2025Filings record

    Director or officer change

  24. 20 Oct 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['BUD', 'TRD']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4690667
  25. 1 Oct 2025Lobbying record

    ENOVIS: new lobbying registration (CONSTITUTION PARTNERS) (dated 1 Sep 2025)

  26. 12 Sep 2025Insiders record

    McDonald Damien (Chief Executive Officer) bought 6,457 shares of ENOV ($199,973) (dated 11 Sep 2025)

  27. 26 Aug 2025Insiders change

    had 3 insiders buy $464K of its shares on the open market within 30 days (3 filings).

    Who bought: Pryor Daniel A, Berry Phillip Benjamin (Ben), Tandy Bradley J.

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $464K
    Window
    27 Jul 2025 to 26 Aug 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  28. 26 Aug 2025Insiders record

    Tandy Bradley J (SVP and Chief Legal Officer) bought 3,200 shares of ENOV ($100,512) (dated 25 Aug 2025)

  29. 21 Aug 2025Insiders record

    BERRY PHILLIP BENJAMIN (BEN) (SVP, Chief Financial Officer) bought 2,500 shares of ENOV ($74,275) (dated 20 Aug 2025)

  30. 15 Aug 2025Insiders record

    PRYOR DANIEL A (EVP, Strategy & Business Dev.) bought 10,000 shares of ENOV ($289,000) (dated 14 Aug 2025)

  31. 2 Apr 2025Filings record

    Director or officer change

  32. 14 Mar 2025Filings record

    Director or officer change

  33. 26 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 26 Feb 2025Filings record

    Director or officer change

  35. 22 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 22 May 2024Filings record

    Director or officer change

  37. 19 Apr 2024Lobbying record

    ENOVIS: new lobbying registration (HEALTH POLICY SOURCE, INC.) (dated 15 Apr 2024)

  38. 16 Apr 2024Lobbying record

    ENOVIS CORPORATION: lobbying engagement terminated (BROWNSTEIN HYATT FARBER SCHRECK, LLP) (dated 1 Mar 2024)

  39. 14 Feb 2024Institutional holdings change

    saw 51 13F filers open a new position in the quarter ended 31 Dec 2023, 1.8× the same quarter last year.

    Same quarter last year: 28; its normal quarter is 35.5.

    See the evidence
    This period
    51 (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    35.5
    Typical spread (median absolute deviation)
    1
    How far from its usual level
    +4.4
    Same quarter last year
    28
    History used
    3,744 days
    2021-12-31: 472022-03-31: 362022-06-30: 352022-09-30: 362022-12-31: 282023-03-31: 342023-06-30: 362023-09-30: 312023-12-31: 51
    the quarter ended 31 Dec 20238 earlier quartersnormal: 35.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  40. 3 Jan 2024Filings record

    Completed an acquisition or asset sale

Showing the newest 40 of 89 entries; narrow the window or the kind of data to see older ones.

Not listed: 255 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001420800
Ticker
ENOV
Domain
enovis.com
Employer name
djo, Encore Medical LP, Encore Medical LP, a subsidiary of Enovis Corporation, ENOVIS CORPORATION (3 unverified)
Fein
74-2863979 (1 unverified)
Hq location
TX|LEWISVILLE|75067 (1 unverified)
Lobbying client
colfax, enovis
Name
Armac, Inc, Athena Finance Limited, Cefar-Compex Medical AB, Chattanooga Europe, B.V and 81 more
  • DOL H-1B labor condition applications and PERM certifications38 data points29 Aug 2022 to 17 Aug 2026
  • Federal lobbying disclosures (LDA)12 records, 240 data points31 Dec 2005 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)149 records6 Jan 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1175 data points31 Dec 2008 to 30 Oct 2026
  • SEC Form 4 insider transactions163 records, 404 data points5 Jan 2016 to 16 Nov 2026
  • FINRA short interest (twice monthly)329 data points14 Apr 2022 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2326 data points5 Apr 2022 to 20 Nov 2026